Anixa Biosciences Inc
ANIX · XNASCIK 715446fmd_1ETC214KBKHR6B7T9QX8ZSY29G制造业 · 医药制剂模板: 标准
覆盖范围: 2009年11月01日 至 2026年7月31日，共 65 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | 1 | 0 | – | 1 | – | 0 | 0 | – |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 2 | 2 | 7 | 5 | 4 | 6 | 7 | 5 | 6 | 5 |
| 销售、一般及管理费用 | 3 | 4 | 7 | 6 | – | – | – | – | – | – |
| 出售房地产收益 | – | – | – | – | – | 0 | – | – | – | – |
| 营业利润 | (5) | (6) | (14) | (12) | (10) | (13) | (14) | (11) | (14) | (12) |
| 利息费用 | 1 | 1 | – | – | – | – | – | – | – | – |
| 利息及投资收益 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| 税前利润 | (5) | (5) | (14) | (12) | – | – | – | – | – | – |
| 所得税费用 | – | – | – | – | – | – | – | – | – | – |
| 持续经营净利润 | – | – | – | – | – | – | – | – | – | – |
| 净利润 | (5) | (5) | (14) | (12) | (10) | (13) | (14) | (10) | (13) | (11) |
| 归属于普通股股东的净利润 | – | (7) | (14) | (12) | – | – | – | – | – | – |